# Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

> **NCT02353780** · PHASE4 · TERMINATED · sponsor: **Dr. Larry W. Moreland** · enrollment: 10 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
- **DRUG:** Abatacept
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02353780
- **Lead sponsor:** Dr. Larry W. Moreland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2017-12-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2020-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02353780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02353780, "Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02353780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*